Original Research

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Chandra A, Kanth R, Thareja S

Biologics: Targets and Therapy 2019, 13:191-200

Published Date: 25 November 2019